Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) shares are trading lower Monday morning after BofA Securities downgraded the stock and Oppenheimer lowered its price target.
BofA Securities analyst Tazeen Ahmad downgraded BioCryst from a Buy rating to a Neutral rating and announced a $14 price target.
Oppenheimer analyst Justin Kim maintained BioCryst with an Outperform rating and lowered the price target from $20 to $16.
What Happened? On Friday, the company paused enrollment in clinical trials with BCX9930 while it investigates elevated serum creatinine levels seen in some patients.
BioCryst discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.
The company announced Monday that it will present at the 21st Annual Needham Virtual Healthcare Conference on April 14.
BCRX 52-Week Range: $9.23 - $19.99
The stock was down 7.37% at $10.30 at time of publication, according to data from Benzinga Pro.
Photo: fernandozhiminaicela from Pixabay.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!